Novexel’s NXL104/ceftazidime Combination Commences Phase II Clinical Trial
14-Nov-2008 -
Novexe announced that its most advanced injectable antibacterial, which combines Novexel’s broad spectrum beta-lactamase inhibitor, NXL104, with the well established cephalosporin antibiotic, ceftazidime, has entered Phase II clinical trials.
The initial Phase II trial with NXL104/ceftazidime ...
antibiotics
bacteria
ciprofloxacin
+4